Comparative Pharmacology
Head-to-head clinical analysis: BRIVIACT versus FYCOMPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIVIACT versus FYCOMPA.
BRIVIACT vs FYCOMPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brivaracetam is a synaptic vesicle glycoprotein 2A (SV2A) ligand with high affinity. The exact mechanism by which it exerts its antiepileptic effect is unknown, but binding to SV2A is thought to modulate neurotransmitter release.
Non-competitive AMPA receptor antagonist; inhibits glutamate-mediated excitatory neurotransmission by selectively targeting AMPA receptors.
50 mg orally twice daily; may increase up to 100 mg twice daily based on response and tolerability.
Initial: 2 mg orally once daily; titrate weekly by 2 mg increments to maintenance dose of 4-12 mg once daily depending on seizure type and tolerability; maximum 12 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 7–11 hours). This supports a twice-daily dosing regimen (e.g., 50 mg twice daily) with steady state achieved within approximately 2 days.
Terminal elimination half-life is approximately 105 hours (range 80-120 hours) in patients with epilepsy; supports once-daily dosing.
Approximately 95% of the dose is excreted in urine as metabolites or unchanged drug (<1% unchanged). About 0.8% is excreted in feces via biliary elimination.
Renal: approximately 30% as unchanged drug; fecal: approximately 70% (mostly as metabolites, minimal unchanged).
Category C
Category C
Anticonvulsant
Anticonvulsant